NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
Bristol-Myers Squibb
Erasca, Inc.
Sapience Therapeutics
Ohio State University Comprehensive Cancer Center
St. Jude Children's Research Hospital
Shanghai Juncell Therapeutics
Linnaeus Therapeutics, Inc.